Posted by Michael Wonder on 14 Feb 2023
NATCO files generic olaparib tablets in US
13 February 2023 - NATCO Pharma announces submission of abbreviated new drug application containing a paragraph IV certification with the US FDA for the generic version of olaparib 100 mg and 150 mg tablets.
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic and prostrate cancer.
